|
|
Volumn 12, Issue 2 PART II, 1997, Pages 278-285
|
|
Cost effectiveness of treatment to national cholesterol education panel (NCEP) targets with HMG-CoA reductase inhibitors trial design
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ATORVASTATIN;
COLESTIPOL;
FLUINDOSTATIN;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
MEVINOLIN;
SIMVASTATIN;
ARTICLE;
CHOLESTEROL BLOOD LEVEL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COST BENEFIT ANALYSIS;
DRUG DOSE;
DRUG EFFICACY;
EDUCATION;
GENERAL PRACTICE;
HUMAN;
HYPERLIPIDEMIA;
ISCHEMIC HEART DISEASE;
MAJOR CLINICAL STUDY;
MULTICENTER STUDY;
PATIENT COMPLIANCE;
PERIPHERAL VASCULAR DISEASE;
PRESCRIPTION;
PRIMARY PREVENTION;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
RISK FACTOR;
SECONDARY PREVENTION;
STATISTICAL ANALYSIS;
ANTICHOLESTEREMIC AGENTS;
COST-BENEFIT ANALYSIS;
ENZYME INHIBITORS;
HUMANS;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
HYPERCHOLESTEROLEMIA;
|
|
EID: 0030929240
PISSN: 11707690
EISSN: None
Source Type: Journal
DOI: 10.2165/00019053-199712020-00018 Document Type: Article |
|
Times cited : (9)
|
|
References (2)
|
